Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00920686Phase 2Completed

Study of NXN 188 for the Treatment of Migraine With Aura

Role: lead

NCT00959751Phase 2Completed

Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura

Role: lead

NCT01748877Phase 2Completed

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Role: lead

NCT00877838Phase 2Unknown

Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura

Role: collaborator

All 4 trials loaded